Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing 301–320 of 2552 stories
A recent study highlights spontaneous remission in patients with statin-associated HMGCR-positive immune-mediated necrotizing myopathy following statin withdrawal. This finding could influence treatment strategies for this rare condition.
A new study discusses the potential of interventional genomics to connect germline diagnosis with therapeutic interventions. This approach could enhance treatment strategies for genetic disorders by integrating diagnostic and therapeutic processes.
A new tri-layer model of mirror movements has been proposed based on evidence from transcranial magnetic stimulation (TMS). This research enhances understanding of neurophysiological mechanisms underlying these movements, which could inform future therapeutic strategies.
A recent study provides genomic characterization of Salmonella enterica serotype Saintpaul isolates from horses, contributing to the understanding of this pathogen's genetic diversity. This research may inform future strategies for managing infections in equine populations.
A case report highlights the use of adjunctive hyperbaric oxygen therapy alongside surgery and antifungal treatment for soft tissue mucormycosis. This approach may offer new insights into managing this rare fungal infection.
The Health Resources and Services Administration (HRSA) is seeking public comment on updated criteria for identifying maternity care health professional target areas. This initiative aims to address shortages in maternity care professionals in designated health professional shortage areas.
The HHS has announced the voluntary relinquishment of the VizientTM Patient Safety Organization (PSO) due to non-compliance with the Patient Safety and Quality Improvement Act. This decision underscores the importance of adherence to safety regulations in healthcare organizations.
The ACF plans to award a $2,027,470 cooperative agreement to Global Refuge to enhance the Immigrant and Refugee Information System (IRIS). This funding aims to improve case placement and compliance reporting for the initial resettlement program.
The National Cancer Institute (NCI) is seeking public comment on a proposed data submission request form for the Genomic Data Commons (GDC). This initiative aligns with the Paperwork Reduction Act, allowing stakeholders to provide input before submission to the Office of Management and Budget.
The Office of Management and Budget (OMB) is seeking comments on a proposed collection of information related to Medicaid and CHIP under the Paperwork Reduction Act. This process aims to streamline the approval of low-burden information requests, but does not address significant policy issues.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. This review could affect how health-related information is gathered and reported.
The Office of the Director has announced the renewal of its charter, which is a procedural update. This notice does not indicate any significant changes or new initiatives.
Illinois lawmakers are advocating for an amendment to protect the federal 340B discount drug program from restrictions, aiming to enhance patient access to medications. U.S. Rep. Danny Davis and state Rep. Anna Moeller emphasize the need for transparency and accountability in the program, which is currently criticized for benefiting large hospitals over low-income patients.
Wave Life Sciences will independently advance its RNA editing program for alpha-1 antitrypsin deficiency (AATD) following GSK's return of WVE-006. The competitive landscape is shifting as Wave and Beam Therapeutics emerge as key players in AATD treatment development.
Novo Nordisk's CagriSema demonstrates superior blood sugar and weight reduction compared to Wegovy in a recent diabetes trial. However, it may face challenges competing against Eli Lilly's Zepbound in the obesity market.
An article highlights the experiences of individuals living with Situs Inversus, a rare condition where internal organs are reversed. The piece aims to raise awareness and foster community support for those affected by this unique anatomical arrangement.
Sanofi's drug for Gaucher disease shows promise in recent trials, achieving a 1-for-2 success rate. This development could pave the way for its market entry, following a history of setbacks.
MassBio is hosting the 2026 Rare Disease Day Forum to unite patients, caregivers, advocates, and researchers in raising awareness and celebrating advancements in rare diseases. This event aims to foster community engagement and highlight progress in the field.
The California Institute for Regenerative Medicine has launched the RAPID funding program, allocating $100 million over two years to support therapies for rare diseases. This initiative aims to enhance partnerships and expedite the development of treatments for patients with limited options.
En Carta Diagnostics' EC Pocket Lyme test has received FDA Breakthrough Device Designation, aiming to improve diagnosis for the approximately 476,000 new Lyme disease cases reported annually in the US. This designation may expedite the test's development and review process.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.